fda warning letters compounded semaglutide october 2025 Societies take stand against off-brand GLP-1s over safety concerns Drugmakers battle pharmacies over compounded

What is shifting at the federal level On 1 July 2026, the US Centers for Medicare and Medicaid Services launched a temporary 18-month Medicare GLP-1 bridge programme covering Wegovy, Zepbound, and Foundayo for weight management under Part D

Clinical implications of cardiovascular outcome trials in type 2 diabetes

TB-500 has been evaluated in laboratory models studying cellular migration, muscle regeneration, and wound healing

Our patients use peptide therapy for body composition optimization, recovery acceleration after injury or training, sexual health support, appetite and weight regulation, cognitive performance, anxiety support, and anti-aging protocols